cend-1
Peptideexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2018 (NCT03517176)
Timeline
Indications
Mechanism of action
- Vitronectin receptor alphaANTAGONIST
ITGAV antagonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06261359 | Phase 2 | Mar 19, 2024 | Qilu Pharmaceutical Co., Ltd. |
| NCT05121038 | Phase 1/Phase 2 (Phase 2) | Oct 20, 2021 | Cend Therapeutics Inc., University of Kansas |
| NCT05042128 | Phase 2 | Oct 1, 2021 | Australasian Gastro-Intestinal Trials Group, St John of God Subiaco Hospital, Subiaco, University of Adelaide, University of Sydney |
| NCT05052567 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2021 | Cend Therapeutics Inc., Qilu Pharmaceutical Co., Ltd. |
| NCT03517176 | Phase 1 | Jul 31, 2018 | DrugCendR Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cend Therapeutics Inc. | For profit | 2 | 0 | 1 | 2021 |
| Qilu Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 1 | 2021 |
| Australasian Gastro-Intestinal Trials Group | Academic/Hospital | 1 | 0 | 1 | 2021 |
| DrugCendR Inc. | For profit | 1 | 1 | 1 | 2018 |
| St John of God Subiaco Hospital, Subiaco | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Adelaide | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Sydney | Academic/Hospital | 1 | 1 | 1 | 2021 |
8 organizations
Page 1 / 1